THE DEAL, AT A GLANCE
From the announcementAjax Therapeutics
01Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedAjax Therapeutics raised $85M Series BFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersAjax Therapeutics is positioning AJ1-10959 as an AI-designed JAK2 inhibitor for myeloproliferative diseases where patients who fail current JAK inhibitors have no…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Ajax Therapeutics · Financing Record
Explore source-linked visual explanations for Ajax Therapeutics. Unsupported claims are withheld while source review continues.
Record 1645 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →